Moleculin Biotech, Inc. Comprehensive Income
Moleculin Biotech, Inc. (MBRX) reported Comprehensive Income of -$7.65 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-13
- Moleculin Biotech, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$7.65M.
- Moleculin Biotech, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$12.91M.
- Moleculin Biotech, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was $15.61M.
- Moleculin Biotech, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$25.41M.
- Moleculin Biotech, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$33.51M.
- Moleculin Biotech, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$26.08M.
- Moleculin Biotech, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$29.79M.
- Moleculin Biotech, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$29.05M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$7.65M 10-Q · filed 2026-08-13 | -$20.55M 10-Q · filed 2026-08-13 | -$4.95M derived: sum of 3 quarters · filed 2026-08-13 | -$30.35M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | -$12.91M 10-Q · filed 2026-05-14 | $2.70M derived: sum of 2 quarters · filed 2026-05-14 | -$22.71M derived: sum of 3 quarters · filed 2026-05-14 | -$40.52M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $15.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$9.80M derived: sum of 2 quarters · filed 2026-03-18 | -$27.61M derived: sum of 3 quarters · filed 2026-08-13 | -$33.51M 10-K · filed 2026-03-18 | ||||
| 2025-09-30 | -$25.41M 10-Q · filed 2025-11-13 | -$43.21M derived: sum of 2 quarters · filed 2026-08-13 | -$49.12M 10-Q · filed 2025-11-13 | -$55.74M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | -$17.81M 10-Q · filed 2026-08-13 | -$7.64M 10-Q · filed 2025-08-12 | -$23.71M 10-Q · filed 2026-08-13 | -$14.07M 10-Q · filed 2025-08-12 | -$30.34M derived: sum of 3 quarters · filed 2026-08-13 | -$37.35M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | -$5.90M 10-Q · filed 2026-05-14 | -$6.43M 10-Q · filed 2025-05-13 | -$12.53M derived: sum of 2 quarters · filed 2026-05-14 | -$19.54M derived: sum of 3 quarters · filed 2026-05-14 | -$23.85M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2024-12-31 | -$6.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$13.64M derived: sum of 2 quarters · filed 2026-03-18 | -$17.95M derived: sum of 3 quarters · filed 2026-03-18 | -$26.08M 10-K · filed 2026-03-18 | -$21.80M 10-K · filed 2025-03-21 | |||
| 2024-09-30 | -$7.01M 10-Q · filed 2025-11-13 | -$10.58M 10-Q · filed 2024-11-08 | -$11.32M derived: sum of 2 quarters · filed 2025-11-13 | -$19.45M 10-Q · filed 2025-11-13 | -$19.87M 10-Q · filed 2024-11-08 | -$26.57M derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | -$4.31M 10-Q · filed 2025-08-12 | -$9.29M 10-Q · filed 2025-08-12 | -$19.57M derived: sum of 3 quarters · filed 2025-08-12 | -$25.18M derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | -$4.98M 10-Q · filed 2025-05-13 | -$15.25M derived: sum of 2 quarters · filed 2025-05-13 | -$20.87M derived: sum of 3 quarters · filed 2025-05-13 | -$26.85M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | -$10.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | -$15.89M derived: sum of 2 quarters · filed 2025-03-21 | -$21.87M derived: sum of 3 quarters · filed 2025-03-21 | -$29.79M 10-K · filed 2025-03-21 | ||||
| 2023-09-30 | -$5.62M 10-Q · filed 2024-11-08 | -$11.60M derived: sum of 2 quarters · filed 2024-11-08 | -$19.52M 10-Q · filed 2024-11-08 | -$26.28M derived: sum of 4 quarters · filed 2024-11-08 | ||||
| 2023-06-30 | -$5.98M 10-Q · filed 2024-08-13 | -$13.90M 10-Q · filed 2024-08-13 | -$20.66M derived: sum of 3 quarters · filed 2024-08-13 | -$29.29M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | -$7.92M 10-Q · filed 2024-05-10 | -$14.68M derived: sum of 2 quarters · filed 2024-05-10 | -$23.31M derived: sum of 3 quarters · filed 2024-05-10 | -$30.12M derived: sum of 4 quarters · filed 2024-05-10 | ||||
| 2022-12-31 | -$6.76M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | -$15.39M derived: sum of 2 quarters · filed 2024-03-22 | -$22.20M derived: sum of 3 quarters · filed 2024-03-22 | -$29.05M 10-K · filed 2024-03-22 | ||||
| 2022-09-30 | -$8.63M 10-Q · filed 2023-11-13 | -$15.44M derived: sum of 2 quarters · filed 2023-11-13 | -$22.29M 10-Q · filed 2023-11-13 | -$25.12M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | -$6.81M 10-Q · filed 2023-08-10 | -$13.66M 10-Q · filed 2023-08-10 | -$16.49M derived: sum of 3 quarters · filed 2023-08-10 | -$20.88M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | -$6.86M 10-Q · filed 2023-05-10 | -$9.68M derived: sum of 2 quarters · filed 2023-05-10 | -$14.07M derived: sum of 3 quarters · filed 2023-05-10 | -$18.32M derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | -$2.82M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | -$7.22M derived: sum of 2 quarters · filed 2023-03-22 | -$11.47M derived: sum of 3 quarters · filed 2023-03-22 | -$15.92M 10-K · filed 2023-03-22 | ||||
| 2021-09-30 | -$4.39M 10-Q · filed 2022-11-10 | -$8.64M derived: sum of 2 quarters · filed 2022-11-10 | -$13.10M 10-Q · filed 2022-11-10 | -$15.70M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | -$4.25M 10-Q · filed 2022-08-12 | -$8.70M 10-Q · filed 2022-08-12 | -$11.31M derived: sum of 3 quarters · filed 2022-08-12 | -$14.69M derived: sum of 4 quarters · filed 2022-08-12 | ||||
| 2021-03-31 | -$4.45M 10-Q · filed 2022-05-11 | -$7.06M derived: sum of 2 quarters · filed 2022-05-11 | -$10.44M derived: sum of 3 quarters · filed 2022-05-11 | -$20.53M derived: sum of 4 quarters · filed 2022-05-11 | ||||
| 2020-12-31 | -$2.61M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | -$5.99M derived: sum of 2 quarters · filed 2022-03-24 | -$16.08M derived: sum of 3 quarters · filed 2022-03-24 | -$17.32M 10-K · filed 2022-03-24 | ||||
| 2020-09-30 | -$3.38M 10-Q · filed 2021-11-10 | -$13.47M derived: sum of 2 quarters · filed 2021-11-10 | -$14.71M 10-Q · filed 2021-11-10 | -$18.50M derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | -$10.09M 10-Q · filed 2021-08-11 | -$11.33M 10-Q · filed 2021-08-11 | -$15.11M derived: sum of 3 quarters · filed 2021-08-11 | -$19.26M derived: sum of 4 quarters · filed 2021-08-11 | ||||
| 2020-03-31 | -$1.24M 10-Q · filed 2021-05-12 | -$5.03M derived: sum of 2 quarters · filed 2021-05-12 | -$9.18M derived: sum of 3 quarters · filed 2021-05-12 | -$10.40M derived: sum of 4 quarters · filed 2021-05-12 | ||||
| 2019-12-31 | -$3.79M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | -$7.93M derived: sum of 2 quarters · filed 2021-03-24 | -$9.16M derived: sum of 3 quarters · filed 2021-03-24 | -$13.21M 10-K · filed 2021-03-24 | ||||
| 2019-09-30 | -$4.15M 10-Q · filed 2020-11-12 | -$5.37M derived: sum of 2 quarters · filed 2020-11-12 | -$9.42M 10-Q · filed 2020-11-12 | -$12.19M derived: sum of 4 quarters · filed 2020-11-12 | ||||
| 2019-06-30 | -$1.22M 10-Q · filed 2020-08-12 | -$5.28M 10-Q · filed 2020-08-12 | -$8.05M derived: sum of 3 quarters · filed 2020-08-12 | -$10.07M derived: sum of 4 quarters · filed 2020-08-12 | ||||
| 2019-03-31 | -$4.05M 10-Q · filed 2020-05-11 | -$6.82M derived: sum of 2 quarters · filed 2020-05-11 | -$8.85M derived: sum of 3 quarters · filed 2020-05-11 | -$13.96M derived: sum of 4 quarters · filed 2020-05-11 | ||||
| 2018-12-31 | -$2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | -$4.79M derived: sum of 2 quarters · filed 2020-03-19 | -$9.91M derived: sum of 3 quarters · filed 2020-03-19 | -$11.84M 10-K · filed 2020-03-19 | ||||
| 2018-09-30 | -$2.02M 10-Q · filed 2019-11-12 | -$7.14M derived: sum of 2 quarters · filed 2019-11-12 | -$9.07M 10-Q · filed 2019-11-12 | -$12.25M derived: sum of 4 quarters · filed 2019-11-12 | ||||
| 2018-06-30 | -$5.12M 10-Q · filed 2019-08-16 | -$7.05M 10-Q · filed 2019-08-16 | -$10.23M derived: sum of 3 quarters · filed 2019-08-16 | -$13.10M derived: sum of 4 quarters · filed 2019-08-16 | ||||
| 2018-03-31 | -$1.93M 10-Q · filed 2019-05-13 | -$5.11M derived: sum of 2 quarters · filed 2019-05-13 | -$7.98M derived: sum of 3 quarters · filed 2019-05-13 | -$11.40M derived: sum of 4 quarters · filed 2019-05-13 | ||||
| 2017-12-31 | -$3.19M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | -$6.05M derived: sum of 2 quarters · filed 2019-02-21 | -$9.47M derived: sum of 3 quarters · filed 2019-02-21 | -$9.80M 10-K · filed 2019-02-21 | ||||
| 2017-09-30 | -$2.87M 10-Q · filed 2018-11-13 | -$6.29M derived: sum of 2 quarters · filed 2018-11-13 | -$6.62M 10-Q · filed 2018-11-13 | |||||
| 2017-06-30 | -$3.42M 10-Q · filed 2018-08-10 | -$3.75M 10-Q · filed 2018-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |